TCGA-A2-A0D4-01A-11R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 26
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.540
- G2M_CHECKPOINT+0.510
- DNA_REPAIR+0.430
- MYC_TARGETS_V1+0.410
- MYC_TARGETS_V2+0.400
- ESTROGEN_RESPONSE_EARLY+0.330
- MITOTIC_SPINDLE+0.330
- OXIDATIVE_PHOSPHORYLATION+0.320
- ESTROGEN_RESPONSE_LATE+0.310
- ADIPOGENESIS+0.240
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.540
- INFLAMMATORY_RESPONSE-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- IL6_JAK_STAT3_SIGNALING-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- KRAS_SIGNALING_UP-0.390
- INTERFERON_GAMMA_RESPONSE-0.380
- COMPLEMENT-0.240
- COAGULATION-0.220
- APICAL_SURFACE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013542 | — | cohortSQ1 | 0.897 |
| 2 | e235012b-4b29-478a-abad-6a70cd949cfa | — | — | 0.877 |
| 3 | AUR-AE5G-TTM1-A-1-1-R-A742-41 | — | C | 0.872 |
| 4 | TCGA-B6-A0WV-01A-11R-A109-07 | — | B | 0.871 |
| 5 | TCGA-A8-A079-01A-21R-A00Z-07 | — | B | 0.869 |
| 6 | s0094236 | — | — | 0.867 |
| 7 | TCGA-77-8143-01A-11R-2247-07 | — | cohortSQ1 | 0.864 |
| 8 | TCGA-XF-A8HB-01A-11R-A36F-07 | — | — | 0.858 |
| 9 | 9f6a2480-748d-414b-be0b-36be34c24037 | — | — | 0.854 |
| 10 | TCGA-B6-A0X5-01A-21R-A109-07 | — | B | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.430 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.330 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.310 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |